恒大健康(00708):恒驰电动车料明年下半年量产
恒大健康(00708)副主席刘永灼透露,上海及广州生产基地首期规划产能共40万辆,下月起可试产,料明年下半年实现量产,期望正式销售後很快可实现盈利及收支平衡。
公司於2018年底入股汽车销售商广汇汽车,他指出,广汇拥有逾800个销售网点,公司亦正计划开设36个恒驰展示体验中心、1,600家营销中心及3,000个维修售後服务网点,相信在未来3至5年内年产销可达100万辆。
首席财务官潘大荣指,针对电动车业务2019年投资约147亿元人民币(下同),主要用於股权收购、基地建设、研发支出,今年上半年已投入30亿元,下半年料再投入27亿元以收购股权,明年计划投资90亿元,即总投资达到294亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.